Wooburn, United Kingdom

Stephen Keith Rhind


Average Co-Inventor Count = 1.5

ph-index = 3

Forward Citations = 73(Granted Patents)


Location History:

  • Berkshire, GB (1992)
  • Wooburn, GB (1994 - 1998)
  • Buckinghamshire, GB (2003)

Company Filing History:


Years Active: 1992-2003

Loading Chart...
4 patents (USPTO):Explore Patents

Of course! Here is the article for inventor Stephen Keith Rhind:

Title: Innovator Spotlight: Stephen Keith Rhind, Pioneer in Cross-Linked Antibodies

Introduction:

Stephen Keith Rhind, a prominent inventor based in Wooburn, GB, is renowned for his groundbreaking work in the field of cross-linked antibodies. With a total of 4 patents to his name, Rhind has made significant contributions to the advancements in antibody technologies.

Latest Patents:

Rhind's latest patents focus on the development of cross-linked antibodies and processes for their preparation. These innovative conjugates exhibit enhanced binding capacity and excellent blood clearance in vivo, making them invaluable for the diagnosis and therapy of tumors. By incorporating reporter or effector molecules into the interchain bridges of the antibodies, Rhind has revolutionized the field of antibody conjugates.

Career Highlights:

Having worked at esteemed companies such as Celltech Limited and Celltech Therapeutics Limited, Rhind has showcased his expertise in the biotechnology industry. His pioneering research in cross-linked antibodies has paved the way for novel diagnostic and therapeutic applications in the treatment of tumors.

Collaborations:

Throughout his career, Rhind has collaborated with esteemed colleagues such as Alan D Bennett and Peter Anthony Lowe. Together, they have pushed the boundaries of antibody technology, creating innovative solutions for cancer diagnosis and therapy.

Conclusion:

In conclusion, Stephen Keith Rhind stands out as a visionary inventor in the realm of cross-linked antibodies. His patents and collaborations reflect a commitment to innovation and excellence in the field of biotechnology, shaping the future of antibody-based therapeutics.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…